

FILE 'REGISTRY' ENTERED AT 10:27:48 ON 30 DEC 2009

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e water/cn

E1 1 WATCON 1255/CN
E2 1 WATCON 130/CN
E3 1 --> WATER/CN
E4 1 WATER ((H2O)2)/CN
E5 1 WATER (D218O)/CN
E6 1 WATER (D2O1+)/CN
E7 1 WATER (DOT), HEAVY/CN
E8 1 WATER (DTO)/CN
E9 1 WATER (H17OH)/CN
E10 1 WATER (H214O)/CN
E11 1 WATER (H215O)/CN
E12 1 WATER (H217O)/CN

=> e

E13 1 WATER (H218O)/CN
E14 1 WATER (H2O1+)/CN
E15 1 WATER (HD16O)/CN
E16 1 WATER (HDO)/CN
E17 1 WATER (HDO1+)/CN
E18 1 WATER (HTO)/CN
E19 1 WATER (T218O)/CN
E20 1 WATER (T2O)/CN
E21 1 WATER (TOH)/CN
E22 1 WATER BLACK/CN
E23 1 WATER BLACK 100/CN
E24 1 WATER BLACK 100L/CN

=> e water,heavy/cn

E25 1 WATER, UNDECAMER/CN
E26 1 WATER, UNDECAMER, RADICAL ION(1-)/CN
E27 0 --> WATER,HEAVY/CN
E28 1 WATER-14O/CN
E29 1 WATER-15O/CN
E30 1 WATER-17O/CN
E31 1 WATER-17O ION(1+)/CN
E32 5 WATER-17O, COBALT COMPLEX/CN
E33 1 WATER-17O, COMPD. WITH BARIUM CHLORATE (1:1:2)/CN
E34 1 WATER-17O, COMPD. WITH ETHANEDIOIC-17O4 ACID (2:1)/CN
E35 1 WATER-17O, COMPD. WITH ETHENE (1:1)/CN
E36 1 WATER-17O, COMPD. WITH GLYCYLGLYCYL-L-VALINE (2:1)/CN

=> e water, heavy/CN

E37 1 WATER, EICOSAMER/CN
E38 1 WATER, EICOSAMER, RADICAL ION(1-)/CN
E39 1 --> WATER, HEAVY/CN
E40 1 WATER, HEAVY (D217O)/CN

E41 1 WATER, HEAVY (D218O)/CN
 E42 1 WATER, HEAVY (D2O)/CN
 E43 1 WATER, HEAVY (D2O), COMPD. WITH ALUMINUM CHLORIDE (6:1)/CN
 E44 1 WATER, HEAVY (D2O), COMPD. WITH ALUMINUM SULFATE (ALH(SO4)2)
 AND GUANIDINE (6:1:1)/CN
 E45 1 WATER, HEAVY (D2O), COMPD. WITH AMMONIUM LITHIUM TARTRATE-O,
 O-D2 (1:1)/CN
 E46 1 WATER, HEAVY (D2O), COMPD. WITH AMMONIUM SODIUM TARTRATE-O,O
 -D2 (4:1)/CN
 E47 1 WATER, HEAVY (D2O), COMPD. WITH BARIUM HYDROXIDE (BA(OD)2) (
 1:1)/CN
 E48 1 WATER, HEAVY (D2O), COMPD. WITH BERYLLIUM SULFATE (BE(SO4))
 (4:1)/CN

=> s e5-e8, e15-e17

1 "WATER (D218O)"/CN
 1 "WATER (D2O1+)"/CN
 1 "WATER (DOT), HEAVY"/CN
 1 "WATER (DTO)"/CN
 1 "WATER (HD16O)"/CN
 1 "WATER (HDO)"/CN
 1 "WATER (HDO1+)"/CN
 L1 5 ("WATER (D218O)"/CN OR "WATER (D2O1+)"/CN OR "WATER (DOT), HEAVY
 "/CN OR "WATER (DTO)"/CN OR "WATER (HD16O)"/CN OR "WATER (HDO)"
 /CN OR "WATER (HDO1+)"/CN)

=> s e40-42

1 "WATER, HEAVY (D217O)"/CN
 1 "WATER, HEAVY (D218O)"/CN
 1 "WATER, HEAVY (D2O)"/CN
 L2 3 ("WATER, HEAVY (D217O)"/CN OR "WATER, HEAVY (D218O)"/CN OR "WATE
 R, HEAVY (D2O)"/CN)

=> file Biosis Biotechno Biotechds CAplus Pascal

| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
|----------------------|------------|---------|
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 58.78 | 59.00 |

FILE 'BIOSIS' ENTERED AT 10:34:22 ON 30 DEC 2009

Copyright (c) 2009 The Thomson Corporation

FILE 'BIOTECHNO' ENTERED AT 10:34:22 ON 30 DEC 2009

COPYRIGHT (C) 2009 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHDS' ENTERED AT 10:34:22 ON 30 DEC 2009

COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'CAPLUS' ENTERED AT 10:34:22 ON 30 DEC 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PASCAL' ENTERED AT 10:34:22 ON 30 DEC 2009

Any reproduction or dissemination in part or in full,
 by means of any process and on any support whatsoever

is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2009 INIST-CNRS. All rights reserved.

=> s L1 or L2

'CN' IS NOT A VALID FIELD CODE

L3 13224 L1 OR L2

=> deutter? or D2O or (heavy water) or 2H or H2

L4 468708 DEUTTER? OR D2O OR (HEAVY WATER) OR 2H OR H2

=> cell# or cellular

L5 11473650 CELL# OR CELLULAR

=> viab? or living or dead or death or apopto? or live

L6 2083263 VIAB? OR LIVING OR DEAD OR DEATH OR APOPTO? OR LIVE

=> spectra? and (Raman or IR or infrared or (infra(w)red) or "FTIR")

L7 631980 SPECTRA? AND (RAMAN OR IR OR INFRARED OR (INFRA(W) RED) OR "FTIR

=> L3 and L4

L8 9007 L3 AND L4

=> l5 and L8

L9 1072 L5 AND L8

=> l5 and L6

L10 1002301 L5 AND L6

=> L9 and L10

L11 56 L9 AND L10

=> L7 and L8

L12 1012 L7 AND L8

=> (L9 or L10 or L11) and L12

L13 44 (L9 OR L10 OR L11) AND L12

=> L7 and (l8 or L9)

L14 1012 L7 AND (L8 OR L9)

=> l14 and L11

L15 0 L14 AND L11

=> L5 and L6

L16 1002301 L5 AND L6

=> l16 and L14

L17 0 L16 AND L14

=> L4 and L7

L18 19468 L4 AND L7

=> L16 and L18

L19 28 L16 AND L18

=> L4 and L5

L20 57455 L4 AND L5

=> L19 and L20

L21 28 L19 AND L20

=> L6 and L21

L22 28 L6 AND L21

=> dup rem L22

PROCESSING COMPLETED FOR L22

L23 16 DUP REM L22 (12 DUPLICATES REMOVED)

=> L6 and L21

L24 28 L6 AND L21

=> Dup rem L24

PROCESSING COMPLETED FOR L24

L25 16 DUP REM L24 (12 DUPLICATES REMOVED)

=> L25 and pd<20031222

L26 3 L25 AND PD<20031222

=> d bib abs L26 1-3

L26 ANSWER 1 OF 3 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

AN 1985:437783 BIOSIS

DN PREV198580107775; BA80:107775

TI IR SPECTROSCOPIC STUDY OF THE GEL TO LIQUID-CRYSTAL PHASE

TRANSITION IN LIVE ACHOLEPLASMA-LAIDLAWII CELLS.

AU CAMERON D G [Reprint author]; MARTIN A; MOFFATT D J; MANTSCH H H

CS STANDARD OIL RES CENT, CLEVELAND, OH 44128, USA

SO Biochemistry, (1985) Vol. 24, No. 16, pp. 4355-4359.

CODEN: BICHAW. ISSN: 0006-2960.

DT Article

FS BA

LA ENGLISH

AB The temperature dependences of the IR spectra of

H2-labeled plasma membranes of live *A. laidlawii* B

cells and of the isolated plasma membranes demonstrate that the

profiles of the gel to liquid-crystal phase transitions are very

different. At temperatures within the range of the phase transition, the

live mycoplasma is able to keep the fluidity of its plasma

membrane at a much higher value than that of the isolated plasma membrane

at the same temperature. The difference is particularly pronounced at and

around the temperature of growth. Live *A. laidlawii*, grown at

37.degree. C on a fatty acid depleted medium supplemented with myristic

acid (C14:0), pentadecanoic acid (C15:0) or palmitic acid (C16:0), are

highly fluid; i.e., at the temperature of growth, the fractional

population of the liquid-crystalline phase is 95-100% at 37.degree. C,

whereas in the case of the isolated plasma membranes the fractional

population of the liquid-crystalline phase at 37.degree. C is only 58%

(C14:0), 36% (C15:0) or 38% (C16:0).

L26 ANSWER 2 OF 3 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN

AN 2002-18243 BIOTECHDS

TI A new binding motif of Arf protein is involved in binding of Arf and Dm2 to induce formation of beta-strand assembly of Dm2 and is useful to find new compounds for the treatment of cancer or predisposition to cancer; involving vector-mediated recombinant protein gene transfer and expression in host cell for use in cancer therapy

AU KRIWACKI R; BOTHNER B; LEWIS W

PA ST JUDE CHILDREN'S RES HOSPITAL

PI US 20020045192 18 Apr 2002

AI US 2001-956425 19 Sep 2001

PRAI US 2001-956425 19 Sep 2001

DT Patent

LA English

OS WPI: 2002-507238 [54]

AN 2002-18243 BIOTECHDS

AB DERWENT ABSTRACT:

NOVELTY - The amino acid sequence of the Arf motif which binds to Dm2 to induce formation of Dm2 beta-strand assembly, is new.

DETAILED DESCRIPTION - The MAIN CLAIM is for a peptide consisting of the sequence Arg-Xaa-Phe-Xaa-Val-Xaa-Xaa-Xaa-Arg (sequence I) is new. INDEPENDENT CLAIMS are also included for: (i) a fusion protein comprising a peptide consisting of sequence I; (ii) a peptide or fusion protein consisting of two segments of an Arf protein, where each segment consists of sequence I; (iii) a peptide or fusion protein consisting of residues 235-259 of the 491 amino acid sequence fully defined in the specification (sequence II); (iv) a peptide of fusion protein comprising amino acids 275-289 of sequence II; (v) a peptide or fusion protein comprising amino acids 235-259 and 275-289 of sequence II; (vi) a composition comprising two segments of an Arf protein chemically joined via a non-peptide linkage, where each segment comprising sequence I; (vii) identifying a compound that can induce the formation of beta-strand assembly of Dm2, comprising contacting the compound with Dm2 or its inducible fragment and determining if Dm2 or its fragment is induced to form a beta-strand assembly; (viii) a compound identified by the above method which is not a peptide comprising five or more consecutive amino acids comprised by a natural protein; (ix) identifying a compound that can enhance the rate of beta-strand assembly of Dm2 induced by Arf, comprising contacting the compound with Dm2 or its inducible fragment and Arf or its inducible fragment, and determining the rate of formation of beta-strand assembly; (x) identifying a compound that can inhibit the formation of beta-strand assembly of Dm2, comprising contacting the compound with Dm2 or its inducible fragment and Arf or its inducible fragment, and determining the rate of formation of beta-strand assembly; (xi) identifying a compound that can induce the formation of supramolecular assemblies comprised of beta-strands of Dm2, comprising contacting the compound with Dm2 or its inducible fragment and determining if the Dm2 is induced to form supramolecular assemblies comprised of beta-strands of Dm2; (xii) a compound identified by the method in (xi) which is not a peptide comprising five or more consecutive amino acids comprised by a natural protein; (xiii) an antibody raised against a peptide comprising sequence I or residues 235-259 or 275-289 of sequence II, preferably a humanized antibody; (xiv) inducing apoptosis in a cell by administering the above antibody; and (xv) designing a compound that is predicted to mimic the ability of Arf to induce the formation of beta-strand assembly of Dm2,

comprising: (a) generating a computer model of a structure of Arf-Dm2 complex based on the amino acid sequences of the portions of Arf and Dm2 involved in the Arf-Dm2 complex and on the circular dichroism and Fourier Transform Infra-red spectra obtained for the Arf-Dm2 complex, and (b) designing a compound to bind to Dm2 as Arf does using the computer model of the surface of the Arf-Dm2 binding complex, and optionally(c) organically synthesizing the compound (d) contacting the synthesized compound with Dm2 or its inducible fragment, and (e) determining if the Dm2 has formed a beta-strand assembly.

BIOTECHNOLOGY - Preferred methods: Determination of beta-strand assembly is performed by circular dichroism methods, nuclear magnetic resonance, Fourier Transform Infra-red spectroscopy, where the fluorescence of a native tryptophan of Dm2 is monitored or where Dm2 is labeled with a fluorescent probe. Determination of supramolecular assemblies is preferably by size exclusion. The Dm2 is preferably Hdm2 having sequence II and the inducible fragment preferably comprises amino acids 235-259 or 275-289 of sequence II, the H2 segment.

ACTIVITY - Cytostatic.

MECHANISM OF ACTION - Formation of Dm2 beta-strand assembly.

USE - A compound that can induce beta-strand assembly of Hdm2 in a cell is used to treat cancer or predisposition to cancer, particularly where the patient has tumor cells characterized by a lack of sufficient Arf activity to induce cell cycle arrest and/or apoptosis, but which still retain functional p53. The antibody is used to treat a patient with a tumor that contains cells characterized by having functional Arf, functional Hmd2 and functional p53 (claimed). The invention is also used to find compounds that mimic, enhance or inhibit Arf-induced formation of beta-strand assembly of Dm2.

EXAMPLE - No example of isolation or preparation of the claimed molecules, or carrying out the claimed methods is given. (22 pages)

L26 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2002:254835 CAPLUS

DN 137:13421

TI Evaluation of microcrystalline silicon films deposited by ultrafast thermal plasma CVD

AU Chae, Yongkee; Ohno, Hiromasa; Eguchi, Keisuke; Yoshida, Toyonobu

CS Dept of Materials Engineering, The University of Tokyo, Tokyo, 113-8656, Japan

SO Materials Research Society Symposium Proceedings (2001), 664(Amorphous and Heterogeneous Silicon-Based Films), A4.4.1-A4.4.6
CODEN: MRSPDH; ISSN: 0272-9172

PB Materials Research Society

DT Journal

LA English

AB This research is the 1st attempt at applying thermal plasma CVD (TPCVD) for the ultrafast deposition of Si films for solar cells. A conventional deposition process of Si films, such as plasma-enhanced CVD (PECVD), is capable of a max. deposition rate of .apprx.5 .ANG./s and it takes a relatively long time to deposit an intrinsic layer. A novel ultrafast deposition approach using dc-radiofrequency hybrid TPCVD is reported. The extreme improvement of stability, controllability, and cleanliness of the process enabled the deposition of microcryst. Si films

at the ultrafast rate of over 1000 nm/s, which is .apprx.2000 times faster than that by conventional CVD. Also, a min. defect d. of 7.2 .times. 10¹⁶ cm⁻³ was achieved by post-treatment of the film in 2 torr H₂/Ar plasma. Monte-Carlo simulation and step coverage anal. suggested that the precursor is an .apprx.1 nm cluster with a sticking probability of .apprx.0.6. The success of this research will lead to the development of com. viable technol. in a roll-to-roll system in the near future, and will fundamentally change the established concepts of Si deposition technol.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT